A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells

Oncotarget

Volumn 5, Issue 19, 2014, Pages 9007-9021

  Fahrenholtz, Cale D ^a   Greene, Ann M ^a   Beltran, Pedro J ^b   Burnstein, Kerry L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b AMGEN INC   (United States)

Author keywords

AMG 479; Castration resistance; Ganitumab; Insulin like growth factor receptor 1; Phospho proteomics; VCaP

Indexed keywords

CALCIUM; GANITUMAB; INSULIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; CALCIUM CHELATING AGENT; FOCAL ADHESION KINASE 2; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; PHOSPHOLIPASE C GAMMA; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CALCIUM SIGNALING; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROSTATE CANCER CELL LINE; RECEPTOR BLOCKING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; MALE; METABOLISM; PHOSPHORYLATION; PREVENTION AND CONTROL; PROSTATIC NEOPLASMS; TUMOR CELL LINE; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CALCIUM; CALCIUM CHELATING AGENTS; CALCIUM SIGNALING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FOCAL ADHESION KINASE 2; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84910077453     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2346     Document Type: Article

References (48)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29.
2. Breuhahn K, Longerich T and Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006; 25(27):3787-3800.
3. Mendivil A, Zhou C, Cantrell LA, Gehrig PA, Malloy KM, Blok LJ, Burger CW and Bae-Jump VL. AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways. Reprod Sci. 2011; 18(9):832-841.
4. Grothey A, Voigt W, Schober C, Muller T, Dempke W and Schmoll HJ. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, andchemoresistance in solid tumors. J Cancer Res Clin Oncol. 1999; 125(3-4):166-173.
5. Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R and Calzone FJ. Efficacy of ganitumab (AMG 479), alone and in combinationwith rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther. 2011; 337(3):644-654.
6. Riedemann J and Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer. 2006; 13 Suppl 1:S33-43.
7. Samani AA, Yakar S, LeRoith D and Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine reviews. 2007; 28(1):20-47.
8. Baserga R, Hongo A, Rubini M, Prisco M and Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochimica et biophysica acta. 1997; 1332(3):F105-126.
9. Yin M, Guan X, Liao Z and Wei Q. Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res. 2009; 1(2):101-114.
10. Gao J, Chang YS, Jallal B and Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res. 2012; 72(1):3-12.
11. Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, Baserga R, Kendall R, Radinsky R and Calzone FJ. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther. 2009; 8(5):1095-1105.
12. Calzone FJ, Cajulis E, Chung YA, Tsai MM, Mitchell P, Lu J, Chen C, Sun J, Radinsky R, Kendall R and Beltran PJ. Epitope-specific mechanisms of IGF1R inhibition by ganitumab. PloS one. 2013; 8(2):e55135.
13. Fahrenholtz CD, Beltran PJ and Burnstein KL. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Mol Cancer Ther. 2013; 12(4):394-404.
14. Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ and Konecny GE. Ganitumab (AMG 479) Inhibits IGF-II-Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy. Clin Cancer Res. 2014; 20(11):2947-2958.
15. McCaffery I, Tudor Y, Deng H, Tang R, Suzuki S, Badola S, Kindler HL, Fuchs CS, Loh E, Patterson SD, Chen L and Gansert JL. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res. 2013; 19(15):4282-4289.
16. Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams T, Regan E, Brady R, Weber J, Campos T, Kvols LK and Kulke MH. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2013; 20(3):383-390.
17. Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BY, Kopp MV, Sakaeva DD, Mitchell EP, Dubey S, Suzuki S, Hei YJ, Galimi F, McCaffery I, Pan Y and Loberg R. Arandomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol. 2013; 24(7):1777-1785.
18. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E and Fuchs CS. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012.
19. Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M and Tolcher A. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012; 30(15):1849-1856.
20. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G and Puzanov I. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009; 27(34):5800-5807.
21. Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker A and Pollak M. A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res. 2012; 18(12):3407-3413.
22. Dean JP, Sprenger CC, Wan J, Haugk K, Ellis WJ, Lin DW, Corman JM, Dalkin BL, Mostaghel E, Nelson PS, Cohen P, Montgomery B and Plymate SR. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab. 2013; 98(5):E820-828.
23. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL and Plymate SR. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. 2005; 11(8): 3065-3074.
24. Wu JD, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL and Plymate SR. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res. 2006; 12(20 Pt 1):6153-6160.
25. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I and Plymate SR. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem. 2006; 99(2):392-401.
26. Konijeti R, Koyama S, Gray A, Barnard RJ, Said JW, Castor B, Elashoff D, Wan J, Beltran PJ, Calzone FJ, Cohen P, Galet Cand Aronson WJ. Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts. Mol Cancer Ther. 2012; 11(7):1539-1546.
27. Korenchuk S, Lehr JE, McLean L, Lee YG, Whitney S, Vessella R, Lin DL and Pienta KJ. VCaP, a cell-based model system of human prostate cancer. In Vivo. 2001; 15(2):163-168.
28. Loberg RD, St John LN, Day LL, Neeley CK and Pienta KJ. Development of the VCaP androgen-independent model of prostate cancer. Urol Oncol. 2006; 24(2):161-168.
29. Jiang X, Chen S, Asara JM and Balk SP. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem. 2010; 285(20):14980-14989.
30. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S and Li Y. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010; 17(5):443-454.
31. Lipinski CA and Loftus JC. Targeting Pyk2 for therapeutic intervention. Expert opinion on therapeutic targets. 2010; 14(1):95-108.
32. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H and Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005; 65(16):7052-7058.
33. Jegg AM, Ward TM, Iorns E, Hoe N, Zhou J, Liu X, Singh S, Landgraf R and Pegram MD. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. Breast cancer research and treatment. 2012; 136(3):683-692.
34. Ciapa B, Pesando D, Wilding M and Whitaker M. Cell-cycle calcium transients driven by cyclic changes in inositol trisphosphate levels. Nature. 1994; 368(6474): 875-878.
35. Taylor JT, Zeng XB, Pottle JE, Lee K, Wang AR, Yi SG, Scruggs JA, Sikka SS and Li M. Calcium signaling and T-type calcium channels in cancer cell cycling. World journal of gastroenterology: WJG. 2008; 14(32): 4984-4991.
36. Berridge MJ. Calcium Signaling and Cell-Proliferation. Bioessays. 1995; 17(6):491-500.
37. Dupont J, Karas M and LeRoith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem. 2000; 275(46):35893-35901.
38. Kahl CR and Means AR. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocrine reviews. 2003; 24(6):719-736.
39. Fixemer T, Wissenbach U, Flockerzi V and Bonkhoff H. Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene. 2003; 22(49):7858-7861.
40. Monteith GR, Davis FM and Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem. 2012; 287(38):31666-31673.
41. Davis FM, Azimi I, Faville RA, Peters AA, Jalink K, Putney JW, Jr., Goodhill GJ, Thompson EW, Roberts-Thomson SJ and Monteith GR. Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene. 2013.
42. Li X, Zhou L, Feng YH, Abdul-Karim FW and Gorodeski GI. The P2X7 receptor: a novel biomarker of uterine epithelial cancers. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1906-1913.
43. Panner A, Cribbs LL, Zainelli GM, Origitano TC, Singh S and Wurster RD. Variation of T-type calcium channel protein expression affects cell division of cultured tumor cells. Cell calcium. 2005; 37(2):105-119.
44. Tsavaler L, Shapero MH, Morkowski S and Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 2001; 61(9):3760-3769.
45. Zhang L and Barritt GJ. Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells. Cancer Res. 2004; 64(22): 8365-8373.
46. Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W and Burnstein KL. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene. 2012; 31(6): 716-727.
47. Peacock SO, Fahrenholtz CD and Burnstein KL. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol. 2012; 26(12):1967-1979.
48. Wu F, Peacock SO, Rao S, Lemmon SK and Burnstein KL. Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth. J Biol Chem. 2013; 288(8):5463-5474.